Chimeric switch receptor were also designed by combining the IL-4R extracellular domain with the intracellular signaling domains of IL-7 or IL-21, resulting in CAR T cells with enhanced anti-tumor activity against IL-4+ tumors (227, 228). Here, IL21 is linked to neoplasm.